Researchers at Biotech companies exploring new ways of cancer treatments

Oncolytics Biotech CEO, Thompson while taking forward the CBS’60 Minutes report on cancer treatments that are vrisu-based, said that there were many more angles to be considered with the treatment. In a report published in Forbes recently, it was explained that the show was focused on the engineered polio virus which was created at the Duke University in order to treat a fatal kind of brain cancer, glioblastoma.

Thompson said that he is not just aware about such treatments, but also understands the complexity of bringing them into the market. Oncolytics Biotech, which was formed in 1998, explains a range of discoveries that have been done at the University of Calgary. These discoveries focus on the reovirus, which is also a kind of brain cancer treatment. This company has already done the Phase I trials of the therapy based on this reovirus and it is called Reolysin. It is used in treating neck as well as head cancers.

Though there have not been very successful results of the trials, but the company CEO says that they will continue to fish out other treatments for virus-based immunotherapy as well as polio.

There are various companies that are working in the same direction. In the entire field of biology, there is a whole lot of research that is being done. While the companies are learning to deal with the plunging shares, the scientists on the other hand, are learning to materialize and learn from the failed trials.

However, there is a bleak difference between what other researchers are doing and the approach of Oncolytics. This company’s Reolysin is said to be a naked form of the already-existing virus. This treatment has not specifically been created to fight the tumor cells or increase the ability of immune system in dealing with the cancer. The primary ability of Reovirus is to protect the normal cells instead. It will work only on the tumor cells which have the capability of genetic mutations.